Skip to content

ANI Pharmaceuticals

US · ANIP #2919 by market cap Listed 1970
68.55 -0.58 -0.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 68.94 -0.27%
After-hours 68.55 0.00%
86.0367.4168.552026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ANIP?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -12.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation B+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 13.6x Better than 63%
Forward P/E 14.1x Better than 59%
Price / Sales 1.6x Better than 65%
P/E vs own 5-yr range 60th pctl Better than 49%
Growth A

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 40.8% Better than 94%
Net income CAGR (3Y) 15.7% Better than 67%
Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 61.4% Better than 76%
Operating margin 9.2% Better than 49%
Net margin 7.9% Better than 53%
Return on equity 14.9% Better than 68%
Return on invested capital 7.9% Better than 60%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -9.0% Better than 53%
6-month return -17.1% Better than 30%
12-month return (ex latest month) -8.9% Better than 24%
Distance below 52-week high 21.9% Better than 56%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.7x Better than 69%
Debt to assets 42.8% Better than 23%
Interest coverage 5.8x Better than 60%
Free cash flow / net income 192.6% Better than 75%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 71.4% Better than 49%
Upside to average target 53.4% Better than 68%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.05%
1M -5.67%
3M -11.34%
6M -16.40%
YTD -13.16%
1Y -12.70%
3Y +33.63%
5Y +57.44%

Key statistics

Price & volume

Prev close
69.13
Open
68.96
Day range
68.28 - 70.20
Avg price
68.72
Volume
227.26K
Turnover
15.62M
Amplitude
2.78%
52-week range
67.14 - 87.76

Valuation

P/E
20.65
P/E (TTM)
13.63
P/B
2.44
EPS
3.32
Net profit
75.43M
Net assets
637.11M

Share structure

Market cap
1.56B
Float cap
1.44B
Shares out
22.72M
Float shares
20.96M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 7% of range
67.14 87.76

21.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.22M net over the window

Short interest

Shares short
3.58M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ANI Pharmaceuticals (ANIP)?

ANI Pharmaceuticals last traded at 68.55. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ANI Pharmaceuticals's market cap?

About 1.56B.

What is the P/E ratio of ANI Pharmaceuticals?

The trailing twelve-month P/E is 13.63. The Valuation tab shows it against the stock's own five-year range.

Does ANI Pharmaceuticals pay a dividend?

ANI Pharmaceuticals does not currently pay a regular dividend.

Is ANI Pharmaceuticals a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 105.14, which implies 53.4% upside from the current price. This is not investment advice.

What is ANI Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ANI Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.

ANI Pharmaceuticals discussion 0 comments

Add a comment